Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 7 of 7 entries
View as:

A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)

Phase: N/A Priority: Normal
NCT ID: NCT06812325 Org: User:
Start: 02/03/25 End: 12/31/26 Due: 12/31/27

A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( THRIVE )

Phase: N/A Priority: Normal
NCT ID: NCT05176639 Org: User:
Start: 12/03/21 End: 03/31/25 Due: 03/31/26

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Phase: N/A Priority: Normal
NCT ID: NCT06625411 Org: User:
Start: 08/27/24 End: 11/15/26 Due: 11/15/27

A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED)

Phase: N/A Priority: Normal
NCT ID: NCT06384547 Org: User:
Start: 05/23/24 End: 01/31/26 Due: 01/31/27

An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE)

Phase: N/A Priority: Normal
NCT ID: NCT06179875 Org: User:
Start: 02/01/23 End: 07/31/25 Due: 07/31/26

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)

Phase: N/A Priority: Normal
NCT ID: NCT06625398 Org: User:
Start: 08/27/24 End: 12/15/26 Due: 12/15/27

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2)

Phase: N/A Priority: Normal
NCT ID: NCT06021054 Org: User:
Start: 11/14/23 End: 08/31/25 Due: 08/31/26